BioPharma Resources

Drug Trial Radar · NCT07463521

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

May 27, 2026

Primary completion

Dec 1, 2028

Study completion Jan 22, 2029

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Mar 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to demonstrate the efficacy, safety and tolerability of rozanolixizumab compared with placebo in the treatment of adult study participants with Ocular Myasthenia Gravis.

Conditions

  • Ocular Myasthenia Gravis

Interventions

  • RozanolixizumabDrug

    Rozanolixizumab will be administered by subcutaneous infusion.

  • PlaceboDrug

    Placebo will be administered by subcutaneous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline at Day 43 in (Myasthenia Gravis Impairment Index) MGII ocular score (Patient-Reported Outcome (PRO) part)Time frame: At Day 43

Locations

36 sites in 9 countries. Site status is shown where the registry gives one.

  • Mg0038 10104

    Scottsdale, Arizona · Recruiting

  • Mg0038 10105

    O'Fallon, Illinois · Recruiting

  • Mg0038 10106

    Amherst, New York · Recruiting

  • Mg0038 10102

    Cincinnati, Ohio · Recruiting

  • Mg0038 10103

    Columbus, Ohio · Recruiting

  • Mg0038 10108

    Greenfield, Wisconsin · Recruiting

  • Mg0038 10201

    Montreal, Canada · Recruiting

  • Mg0038 31901

    Beijing, China · Recruiting

  • Mg0038 31911

    Beijing, China · Recruiting

  • Mg0038 31912

    Beijing, China · Recruiting

  • Mg0038 31906

    Chengdu, China · Recruiting

  • Mg0038 31908

    Chongqing, China · Recruiting

  • Mg0038 31907

    Nanchang, China · Recruiting

  • Mg0038 31902

    Suzhou, China · Recruiting

  • Mg0038 20303

    Dijon, France · Recruiting

  • Mg0038 20304

    Nantes, France · Recruiting

  • Mg0038 20301

    Nice, France · Recruiting

  • Mg0038 20302

    Paris, France · Recruiting

  • Mg0038 20305

    Paris, France · Recruiting

  • Mg0038 21403

    Sarajishvili, Georgia · Recruiting

  • Mg0038 21402

    Tbilisi, Georgia · Recruiting

  • Mg0038 20405

    Rüdersdorf, Germany · Recruiting

  • Mg0038 31802

    Kobe, Japan · Recruiting

  • Mg0038 31804

    Minatoku, Japan · Recruiting

  • Mg0038 31805

    Sendai, Japan · Recruiting

  • Mg0038 21204

    Katowice, Poland · Recruiting

  • Mg0038 21203

    Krakow, Poland · Recruiting

  • Mg0038 21206

    Lublin, Poland · Recruiting

  • Mg0038 21202

    Warsaw, Poland · Recruiting

  • Mg0038 20605

    Alicante, Spain · Recruiting

  • Mg0038 20604

    Barcelona, Spain · Recruiting

  • Mg0038 20607

    Barcelona, Spain · Recruiting

  • Mg0038 20611

    Madrid, Spain · Recruiting

  • Mg0038 20606

    Málaga, Spain · Recruiting

  • Mg0038 20602

    Murcia, Spain · Recruiting

  • Mg0038 20603

    Seville, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.